Synthesis and biological evaluation of novel 9-heteroaryl substituted 7-chloro-4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates (TQX) as (R,S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptor antagonists

Chemical and Pharmaceutical Bulletin

Volumn 56, Issue 8, 2008, Pages 1085-1091

  Catarzi, Daniela ^a   Colotta, Vittoria ^a   Varano, Flavia ^a   Filacchioni, Guido ^a   Gratteri, Paola ^a   Sgrignani, Jacopo ^a   Galli, Alessandro ^b   Costagli, Chiara ^b  

^a Laboratorio di Progettazione   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

(R,S) 2 amino 3 (3 hydroxy 5 methylisoxazol 4 yl)propionic acid; Competitive antagonist; Ionotropic glutamate receptor; Triazoloquinoxaline

Indexed keywords

5,7 DICHLOROKYNURENIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 7 CHLORO 4,5 DIHYDRO 4 OXO 8 (1,2,4 TRIAZOL 4 YL) 1,2,4 TRIAZOLO[1,5 A]QUINOXALINE 2 CARBOXYLIC ACID; 7 CHLORO 4,5 DIHYDRO 8 (3 CARBOXYPYRROL 1 YL) 4 OXO 1,2,4 TRIAZOLO[1,5 A]QUINOXALINE 2 CARBOXYLIC ACID; AMPA RECEPTOR ANTAGONIST; DIETHYL 1 (4 CHLORO 2,6 DINITROPHENYL) 1,2,4 TRIAZOLO 3,5 DICARBOXYLATE; ETHYL 7 CHLORO 4,5 DIHYDRO 4 OXO 9 (1,2,4 TRIAZOL 4 YL) 1,2,4 TRIAZOLO[1,5 A]QUINOXALINE 2 CARBOXYLATE; ETHYL 7 CHLORO 4,5 DIHYDRO 4 OXO 9 (PYRROL 1 YL) 1,2,4 TRIAZOLO[1,5 A]QUINOXALINE 2 CARBOXYLATE; ETHYL 7 CHLORO 4,5 DIHYDRO 8 (3 CARBOXYPYRROL 1 YL) 4 OXO 1,2,4 TRIAZOLO[1,5 A]QUINOXALINE 2 CARBOXYLATE; ETHYL 7 CHLORO 4,5 DIHYDRO 9 (3 FORMYLPYRROL 1 YL) 4 OXO 1,2,4 TRIAZOLO[1,5 A]QUINOXALINE 2 CARBOXYLATE; ETHYL 9 AMINO 7 CHLORO 4,5 DIHYDRO 4 OXO 1,2,4 TRIAZOLO[1,5 A]QUINOXALINE 2 CARBOXYLATE; ETHYL N1 (4 CHLORO 2,6 DINITROPHENYL) N2 OXAMIDRAZONATE; ETHYL N1 (4 CHLORO 2,6 DINITROPHENYL) N3 ETHOXALYL N2 OXAMIDRAZONATE; ETHYL N1 (4 CHLORO 2,6 DINITROPHENYL)HYDRAZONO N2 CHLOROACETATE; HETEROCYCLIC COMPOUND; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; QUINOXALINE DERIVATIVE; TQX 173; TQX 197; TRIAZOLOQUINOXALINE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR MODEL; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROPIONIC ACIDS; QUINOXALINES; RECEPTORS, AMPA; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 48949100901     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.56.1085     Document Type: Article

References (48)

1. "Excitatory Amino Acids and Synaptic Transmission," ed. by Wheal H. V., Thomson A. M., Academic Press, London, 1995.
2. "The Ionotropic Glutamate Receptors," ed. by Monaghan D. T., Wenthold R. J., Humana Press, Totowa, New Jersey, 1997.
3. Watkins J. C., Biochem. Soc. Trans., 28, 297-310 (2000).
4. Dingledine R., Borges K., Bowie D., Traynelis S. F., Pharmacol. Rev., 51, 7-61 (1999).
5. Danysz W., Parsons C. G., Pharmacol. Rev., 50, 597-664 (1998).
6. Chase T. N., Oh J. O., Konitsiotis S., J. Neurol., 247 (Suppl. 2), II/36-II/42 (2000).
7. Kew J. N. C., Kemp J. A.. Psycopharmacology, 179, 4-29 (2005).
8. Millan M. J., Psycopharmacology, 179, 30-53 (2005).
9. Bleakman D., Lodge D., Neuropharmacology, 37, 1187-1204 (1998).
10. Bigge C. F., Nikam S. S., Expert Opin. Ther. Patents, 7, 1099-1114 (1997).
11. Bräuner-Osborne H., Egebjerg J., Nielsen E. Ø., Madsen U., Krogsgaard-Larsen P., J. Med. Chem., 43, 2609-2645 (2000).
12. Lees G. J., Drugs, 59, 33-78 (2000).
13. Auberson Y. P., Drugs Future, 26, 463-471 (2001).
14. De Sarro G., Gitto R., Russo E., Ferreri Ibbadu G., Barreca M. L., De Luca L., Chimirri A., Curr. Top. Med. Chem., 5, 31-32 (2005).
15. Madsen U., Stensbøl T. B., Krogsgaard-Larsen P., Curr. Med. Chem., 8, 1291-1301 (2001).
16. Bigge C. F., Boxer P. A., Ortwine D. F., Curr. Pharm. Des., 2, 397-412 (1996).
17. Chimirri A., Gitto R., Zappalà M., Expert Opin. Ther. Patents, 9, 557-570 (1999).
18. Nikam S. S., Kornberg B. E., Curr. Med. Chem., 8, 155-170 (2001).
19. Stensbøl T. B., Madsen U., Krogsgaard-Larsen P., Curr. Pharm. Des., 8, 857-872 (2002).
20. Catarzi D., Colotta V., Varano F., Med. Res. Rev., 27, 239-278 (2007).
21. Loscher W., Wlaz P., Szabo L., Neurosci. Lett., 240, 33-36 (1998).
22. Varano F., Catarzi D., Colotta V., Cecchi L., Filacchioni G., Galli A., Costagli C., Il Farmaco, 52, 179-182 (1997).
23. Colotta V., Catarzi D., Varano F., Cecchi L., Filacchioni G., Galli A., Costagli C., Arch. Pharm. Pharm. Med. Chem., 330, 129-134 (1997).
24. Varano F., Catarzi D., Colotta V., Filacchioni G., Cecchi L., Galli A., Costagli C., Il Farmaco, 53, 752-757 (1998).
25. Varano F., Catarzi D., Colotta V., Cecchi L., Filacchioni G., Galli A., Costagli C., Arch. Pharm. Pharm. Med. Chem., 332, 201-207 (1999).
26. Catarzi D., Colotta V., Varano F., Cecchi L., Filacchioni G., Galli A., Costagli C., J. Med. Chem., 42, 2478-2484 (1999).
27. Catarzi D., Colotta V., Varano F., Cecchi L., Filacchioni G., Galli A., Costagli C., Carlà V., J. Med. Chem., 43, 3824-3826 (2000).
28. Varano F., Catarzi D., Colotta V., Cecchi L., Filacchioni G., Galli A., Costagli C., Eur. J. Med. Chem., 36, 203-209 (2001).
29. Catarzi D., Calotta V., Varano F., Filacchioni G., Galli A., Costagli C., Carlà V., J. Med. Chem., 44, 3157-3165 (2001).
30. Varano F., Catarzi D., Colotta V., Filacchioni G., Galli A., Costagli C., Carlà V., J. Med. Chem., 45, 1035-1044 (2002).
31. Catarzi D., Colotta V., Varano F., Calabri F. R., Filacchioni G., Galli A., Costagli C., Carlà V., J. Med. Chem., 47, 262-272 (2004).
32. Colotta V., Catarzi D., Varano F., Calabri F. R., Filacchioni G., Costagli C., Galli A., Bioorg. Med. Chem. Lett., 14, 2345-2349 (2004).
33. Varano F., Catarzi D., Colotta V., Calabri F. R., Lenzi O., Filacchioni G., Galli A., Costagli C., Deflorian F., Moro S., Bioorg. Med. Chem., 13, 5536-5549 (2005).
34. Calabri F. R., Colotta V., Catarzi D., Varano F., Lenzi O., Filacchioni G., Costagli C., Galli A., Eur. J. Med. Chem., 40, 897-907 (2005).
35. Colotta V., Catarzi D., Varano F., Lenzi O., Filacchioni G., Costagli C., Galli A., Ghelardini C., Galeotti N., Gratteri P., Sgrignani J., Deflorian F., Moro S., J. Med. Chem., 49, 6015-6026 (2006).
36. Homori J., Shimizu-Sasamata M., Okada M., Sakamoto S., J. Med. Chem., 40, 2053-2063 (1997).
37. Hogner A., Greenwood J. R., Liljefors T., Lunn M. L., Egebjerg J., Larsen I. K., Gouaux E., Kastrup J. S., J. Med. Chem., 46, 214-221 (2003).
38. Schrodinger Suite 2006 QM-Polarized Ligand Docking protocol. L.L.C., New York (http://www.schrodinger.com).
39. Cho A. E., Guallar V., Berne B. J., Friesner R., J Comput. Chem., 26, 915-931 (2005).
40. Friesner R., Adv. Protein Chem., 72, 79-104 (2005).
41. Nielsen E. O., Madsen U., Schaumburg K., Brehm L., Krogsgaard-Larsen P., Eur. J. Chem.-Chim. Ther., 21, 433-437 (1986).
42. Mannaioni G., Carlà V., Moroni F., Br. J. Pharmacol., 118, 1530-1536 (1996).
43. De Lean A., Munson P. J., Rodbard D., Am. J. Physiol., 235, E97-E102 (1978).
44. Cheng Y.-C., Prusoff W. H., Biochem. Pharmacol., 22, 3099-3108 (1973).
45. Macromodel v8.5, Schrödinger. L.L.C., New York (http://www. schrodinger.com).
46. Glide v.4.0, Schrödinger. L.L.C., New York, NY, 2005 (http://www.schrodinger.com).
47. Qsite v4.0, Schrödinger. L.L.C., New York, NY, 2005. Jagurar v6.5, Schrödinger. L.L.C., New York, NY, 2005 (http://www.schrodinger.com).
48. Jorgensen W. L., Maxwell D. S., Tirado-Rives J., J. Am. Chem. Soc., 118, 11225-11236 (1996).